The FINANCIAL — LifeScan, Inc., a business within the Johnson & Johnson Diabetes Care Companies and a world leader in blood glucose monitoring, today announced a strategic collaboration through its affiliate Cilag GmbH International with WellDoc Corporation (WellDoc) to advance mobile solutions that can empower Type 2 diabetes patients with real time data and information to improve their health outcomes.
In addition, Johnson & Johnson Innovation – JJDC, Inc. (JJDC) participated with other investors in WellDoc’s Series B financing. This new relationship exemplifies Johnson & Johnson’s cross-sector strategy of collaborating with a wide range of technology companies to create new ways that help people live longer, healthier lives.
“We are continuously working to empower diabetes patients by developing and integrating innovative technologies that can improve both daily experiences and long-term health,” said Val Asbury, World Wide President, LifeScan, Inc. “This exciting collaboration bridges our strong history serving diabetes patients and their healthcare team with WellDoc’s innovative diabetes management platform that has been shown to improve health outcomes. By working together, we look forward to advancing new solutions.”
Through the collaboration both companies will work to integrate LifeScan’s newly launched OneTouch Verio Flex blood glucose monitoring system with built-in Bluetooth Smart Technology and OneTouch Reveal mobile application with WellDoc’s BlueStar diabetes management platform and mobile application, the first mobile prescription therapy approved by the U.S. Food and Drug Administration for Type 2 diabetes. OneTouch Verio Flex features ColorSure technology – a simple, accurate and easy-to-use meter that takes the guesswork out of understanding blood sugar test results for people with diabetes. The integration would provide patients additional smart monitoring tools and real-time motivational, behavioral and educational coaching, which clinical studies have shown improve patient health, according to Johnson & Johnson.
Currently, there are an estimated 21 million people diagnosed with Type 2 diabetes in the U.S. and many don’t test their blood sugar regularly or as recommended by their healthcare professional. In a clinical trial, WellDoc showed that when patients used its diabetes management platform for a 12-month period they had a 1.9 percent decline in glycated hemoglobin level over 12 months compared with a 0.7 percent decrease in the usual care group.